Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-06
1997-06-24
Mullis, Jeffrey C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31335
Patent
active
056418051
ABSTRACT:
Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
REFERENCES:
patent: 4871865 (1989-10-01), Lever, Jr. et al.
patent: 4923892 (1990-05-01), Lever, Jr. et al.
patent: 5116863 (1992-05-01), Oshima et al.
Kamei et al., "Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs," Atarashi Ganka, vol. 11(4), pp. 603-605 (1994) (abstract only).
Kamei et al., "Effect of (Z)-11-[3-(Dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs," Arzneimittelforschung, vol. 45(9), pp. 1005-1008 (1985).
Ohsima et al., "Synthesis and Antiallergic Activity of 11-(Aminoalkylidene)-6,11,dihydrodibenz[b,e]oxepin Derivatives," J. Medicinal Chemistry, vol. 35(11), pp. 2074-1084 (1992).
Sharif et al., "Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases," J. of Pharmacology and Experimental Therapeutics, vol. 278(3), pp. 1252-1261 (1996).
Sharif et al., "Olopatadine (AL-4943A): Pharmacological Profile of a Novel Anti-histaminic/Anti-allergic Drug for Use in Allergic Conjunctivitis," Investigative Ophthalmology & Visual Science, vol. 37(3), p. 1027 (1996) (abstract only).
Spitalny et al., "Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis," Investigative Ophthalmology & Visual Science, vol. 37(3), p. 593 (1996) (abstract only).
Yanni et al., "The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), An Effective Anti-allergic/AntihistamIinic Agent," Investigative Ophthalmology & Visual Science, vol. 37(3), p. 1028 (1996) (abstract only).
Zhang et al., "Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic and Antimuscarinic Activity," Chirality, vol. 6(8), pp. 631-641 (1994).
Church, "Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-allergic Drugs?," Agents and Actions, vol. 18, 3/4, pp. 288-293 (1986).
Clegg et al., "Histamine Secretion from Human Skin Slices Induced by Anti-IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol," Clin Allergy, vol. 15, pp. 321-328 (1985).
Hamilton et al., "Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals," Clinical and Experimental Allergy, vol. 24, pp. 955-959 (1994).
Ikeda et al., "Effects of Oxatomide and KW-4679 on Acetylcholine-Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands," Int. Arch. Allergy Immunol., vol. 106, pp. 157-162 (1995).
Irani et al., "Mast Cell Heterogeneity," Clinical and Experimental Allergy, vol. 19, pp. 143-155 (1989).
Pearce et al., "Effect Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin," Clinical Exp. Immunol.,vol. 17, pp. 437-440 (1974).
Siraganian, "An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine," Anal. Biochem., vol. 57, pp. 383-394 (1974).
"The Lung," Scientific Foundations, Raven Press, Ltd., New York, Ch. 3.4.11 (1991), Schwartz, pp. 601-615.
Kamei et al. "Effect of Certain Antirallergic Drugs on Experimental Conjunctivitis in Guinea Pigs", Atarashii Ganka 11(4) pp. 603-605 1994 (month unavailable).
Hayakawa Eiji
Nakakura Masashi
Robertson Stella M.
Yanni John Michael
Alcon Laboratories Inc.
Kyowa Hakko Kogyo Co. Ltd.
Mullis Jeffrey C.
Ryan Patrick M.
LandOfFree
Topical ophthalmic formulations for treating allergic eye diseas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical ophthalmic formulations for treating allergic eye diseas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical ophthalmic formulations for treating allergic eye diseas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-149542